deferoxamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	792	70-51-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: deferoxamine deferoxamine mesylate deferoxamin desferrioxamine desferrioxamine mesilate deferoxamine mesilate desferrioxamine mesylate	Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Molecular weight: 560.69 Formula: C25H48N6O8 CLOGP: -0.18 LIPINSKI: 3 HAC: 14 HDO: 6 TPSA: 205.84 ALOGS: -3.75 ROTB: 23 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

deferoxamine
deferoxamine mesylate
deferoxamin
desferrioxamine
desferrioxamine mesilate
deferoxamine mesilate
desferrioxamine mesylate

Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.

Molecular weight: 560.69
Formula: C25H48N6O8
CLOGP: -0.18
LIPINSKI: 3
HAC: 14
HDO: 6
TPSA: 205.84
ALOGS: -3.75
ROTB: 23

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
CL (Clearance)	8.33 mL/min/kg	Lombardo F, Berellini G, Obach RS
S (Water solubility)	50 mg/mL	Bocci G, Oprea TI, Benet LZ
BA (Bioavailability)	5 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
t_half (Half-life)	3.05 hours	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	178.35 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	1.35 L/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ

Showing 1 to 7 of 7 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
April 1, 1968	FDA	NOVARTIS

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Serum ferritin increased	228.42	22.88	51	2170	6131	63480670
Laryngitis fungal	88.90	22.88	13	2208	134	63486667
Sickle cell anaemia with crisis	71.43	22.88	20	2201	5983	63480818
Mucormycosis	70.40	22.88	17	2204	2854	63483947
Bacterial sepsis	50.81	22.88	14	2207	3944	63482857
Liver iron concentration increased	41.53	22.88	5	2216	8	63486793
Haemoglobin decreased	37.78	22.88	35	2186	145450	63341351
Iron overload	36.43	22.88	8	2213	883	63485918
Haemosiderosis	34.19	22.88	6	2215	206	63486595
Infective chondritis	30.61	22.88	4	2217	16	63486785

Showing 1 to 10 of 18 entries

Previous1 2Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Serum ferritin increased	173.12	22.21	45	2003	6101	34948782
Blood iron increased	37.47	22.21	9	2039	877	34954006
Spinal X-ray abnormal	34.98	22.21	4	2044	0	34954883
Liver iron concentration increased	31.32	22.21	4	2044	6	34954877
Visual acuity reduced	30.25	22.21	16	2032	16133	34938750
Iron overload	29.13	22.21	8	2040	1325	34953558
Blood creatinine increased	27.97	22.21	31	2017	94945	34859938
Mucormycosis	23.95	22.21	10	2038	5932	34948951
Haemoglobin decreased	23.52	22.21	32	2016	120740	34834143
Myelodysplastic syndrome	22.46	22.21	14	2034	19194	34935689

Showing 1 to 10 of 10 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Serum ferritin increased	295.06	22.16	71	3299	9776	79731242
Fundoscopy abnormal	140.23	22.16	18	3352	47	79740971
Mucormycosis	81.61	22.16	25	3345	8444	79732574
Laryngitis fungal	78.90	22.16	12	3358	134	79740884
Spinal X-ray abnormal	52.87	22.16	7	3363	25	79740993
Visual acuity reduced	51.32	22.16	25	3345	29444	79711574
Liver iron concentration increased	48.94	22.16	6	3364	9	79741009
Sickle cell anaemia with crisis	46.24	22.16	16	3354	7906	79733112
Haemoglobin decreased	44.96	22.16	51	3319	222068	79518950
Iron overload	43.43	22.16	11	3359	1853	79739165

Showing 1 to 10 of 22 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	V03AC01	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Iron chelating agents
CHEBI has role	CHEBI:26672	siderochromes
CHEBI has role	CHEBI:38157	iron chelating agents
CHEBI has role	CHEBI:173084	ferroptosis inhibitors
CHEBI has role	CHEBI:50247	antidotes
FDA EPC	N0000175522	Iron Chelator
FDA MoA	N0000000144	Iron Chelating Activity
MeSH PA	D002614	Chelating Agents
MeSH PA	D007502	Iron Chelating Agents
MeSH PA	D064449	Sequestering Agents

Showing 1 to 10 of 11 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Poisoning by iron AND/OR its compounds	indication	55381001
Chronic Iron Overload	indication

Showing 1 to 2 of 2 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.38	acidic
pKa2	8.99	acidic
pKa3	9.53	acidic
pKa4	13.04	acidic
pKa5	13.65	acidic
pKa6	10.56	Basic

Showing 1 to 6 of 6 entries

Previous1Next

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Hypoxia-inducible factor 1-alpha	Transcription factor	Q16665	HIF1A_HUMAN		EC50	4.75		CHEMBL
Deoxyhypusine hydroxylase	Enzyme	Q9BU89	DOHH_HUMAN		IC50	5.30		CHEMBL

Showing 1 to 2 of 2 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
001089	NDDF
004540	NDDF
138-14-7	SECONDARY_CAS_RN
1682	INN_ID
2973	PUBCHEM_CID
3131	RXNORM
372825006	SNOMEDCT_US
387224002	SNOMEDCT_US
4018789	VANDF
4019705	VUID

Showing 1 to 10 of 25 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Deferoxamine	Human Prescription Drug Label	1	63323-597	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	95 mg	INTRAVENOUS	ANDA	17 sections
Deferoxamine	Human Prescription Drug Label	1	63323-599	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	95 mg	INTRAVENOUS	ANDA	17 sections
Deferoxamine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2336	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	30 sections
Deferoxamine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2336	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	30 sections
Deferoxamine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2337	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	30 sections
Deferoxamine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2337	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	30 sections
Deferoxamine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	47781-623	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	12 sections
Deferoxamine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	47781-623	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	12 sections
Deferoxamine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	47781-624	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	12 sections
Deferoxamine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	47781-624	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	12 sections

Showing 1 to 10 of 24 entries

Previous1 2 3Next